RxDoctor Payments Data

Angela Gauthier

Ophthalmology · Baltimore, MDNPI 1982108247

Payments from drug & device makers

$2,133in general payments, 2019–2025

Across 45 payments — averaging $47.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Dompe US, Inc.$244
  • Biotissue Holdings Inc.$231
  • Bausch & Lomb Americas Inc.$121
  • Glaukos Corporation$92
  • Johnson & Johnson Surgical Vision, Inc.$84
  • plus $169 from 5 others

What the payments were for

  • Food & beverage$2,133100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,133 in reported general payments places this provider in the 60th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$158,636
Medicare patients
337
Services billed
1,202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj13$362,266
Prednisolone Acetate686$17,883
Ofloxacin322$3,214
Cyclosporine13$3,089
MoxifloxacinMoxifloxacin Hcl86$1,943
Brimonidine Tartrate25$948
Ketorolac Tromethamine54$831
Latanoprost73$676
ErythromycinErythromycin Base30$370
Timolol Maleate30$188
Dorzolamide Hcl12$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$244$362,26613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →